Premium
Amiodarone and Parkinsonism: a pharmacovigilance study
Author(s) -
Montastruc JeanLouis,
Durrieu Geneviève
Publication year - 2021
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/fcp.12618
Subject(s) - parkinsonism , pharmacovigilance , amiodarone , medicine , odds ratio , antipsychotic , dronedarone , population , pharmacology , adverse effect , psychiatry , schizophrenia (object oriented programming) , disease , atrial fibrillation , environmental health
Background Some case reports have described parkinsonism with amiodarone. We investigated a putative association between parkinsonism and exposure to amiodarone. Methods We used the WHO pharmacovigilance database (VigiBase ® ). All adverse drug reactions with ‘Parkinson‐like events’ and amiodarone were included. Four disproportionality analyses were performed: 1/after inclusion of all reports, 2/according to sex, 3/for the twenty last years (2000–2019), and 4/after exclusion of concomitant drugs known to induce parkinsonism (antipsychotic, antivertigo, antiemetic antinauseant drugs, flunarizine). Results are expressed as reporting odds ratios (ROR; 95% CI) and information component (IC). Results No significant association was found in the whole population [ROR = 0.83 (0.65–1.06), IC = −0.7 (IC 025 = −0.65)], in men, in women, for the 2000–2019 years, or after exclusion of drugs inducing parkinsonism. Conclusion We failed to find any signal of parkinsonism with amiodarone. We suggest that reports of parkinsonism with amiodarone could be mainly explained by other underlying causes.